Up a level |
Macgregor, Callum J, Thomas, Chris D, Roy, David B, Beaumont, Mark A, Bell, James R, Brereton, Tom, Bridle, Jon R, Dytham, Calvin, Fox, Richard, Gotthard, Karl et al (show 10 more authors)
(2019)
Climate-induced phenology shifts linked to range expansions in species with multiple reproductive cycles per year.
NATURE COMMUNICATIONS, 10 (1).
4455-.
Mobasheri, Ali, Fox, Richard, Evans, Iain, Cullingham, Fay, Martín-Vasallo, Pablo and Foster, Christopher S
(2003)
Epithelial Na, K-ATPase expression is down-regulated in canine prostate cancer; a possible consequence of metabolic transformation in the process of prostate malignancy.
Cancer Cell International, 3 (1).
p. 8.
Blacklock, Kelly Bowlt, Birand, Zeynep, Biasoli, Deborah, Fineberg, Elena, Murphy, Sue, Flack, Debs, Bass, Joyce, Di Palma, Stefano, Blackwood, Laura, McKay, Jenny et al (show 5 more authors)
(2018)
Identification of molecular genetic contributants to canine cutaneous mast cell tumour metastasis by global gene expression analysis.
PLOS ONE, 13 (12).
e0208026-.
Li, Wenhao, Sheridan, David, McPherson, Stuart, Alazawi, William, Abeysekera, Kush, Marjot, Tom, Brennan, Paul, Mahgoub, Sara, Cacciottolo, Tessa, Hydes, Theresa ORCID: 0000-0002-7768-6886 et al (show 76 more authors)
(2023)
National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022.
JHEP Reports, 5 (12).
p. 100897.
Meyer, Tim, Fox, Richard, Ma, Yuk Ting, Ross, Paul J, James, Martin W, Sturgess, Richard, Stubbs, Clive, Stocken, Deborah D, Wall, Lucy, Watkinson, Anthony et al (show 8 more authors)
(2017)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2 (8).
pp. 565-575.
Berhane, Sarah, Fox, Richard, Garcia-Finana, Marta ORCID: 0000-0003-4939-0575, Cucchetti, Alessandro and Johnson, Philip ORCID: 0000-0003-1404-0209
(2019)
Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment.
British Journal of Cancer, 121 (2).
pp. 117-124.